Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
To evaluate the effectiveness and safety of forodesine in CLL patients
Chronic Lymphocytic Leukemia (CLL)
DRUG: forodesine HCl
Overall response rate, Up to 6 cycles of therapy
To investigate the efficacy (complete response \[CR\] + partial response \[PR\]) of forodesine in treating subjects with CLL who have failed at least one prior treatment regimen or who are treatment na√Øve but are either elderly, have poor performance status or are otherwise predicted not to tolerate cytotoxic chemotherapy.